Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

969472

registered interest
date	07/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 January 2018 to Question 147424 on Radiotherapy, when the postcode-level dataset which will enable the calculation of travel times to radiotherapy centres will be published.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	171667
answer	answer is ministerial correction date of answer 12/09/2018 answer text <p>In June 2018, The National Cancer Registration and Analysis Service (NCRAS) published three reports relating to patient travel times and cancer, in response to the Independent Cancer Taskforce recommendation 27.</p><p> </p><p>The reports are available at the following link:</p><p> </p><p><a href="http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/travel_times" target="_blank">http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/travel_times</a></p><p> </p><p>The reports cover the following topics:</p><p>- Travel Times and Methodology summarises NCRAS’ investigations of several possible ways of calculating travel times;</p><p>- Travel Times and Cancer Survival is an overview of survival for the four most common cancers, relative to travel time to the nearest hospital with a relevant multidisciplinary team; and</p><p>- Travel Times and Cancer Treatment is a report on treatment with radiotherapy for localised prostate cancer, relative to travel time to a radiotherapy centre.</p><p> </p><p>Postcode-level data is potentially disclosive and is therefore not made routinely available. Such data may be made available to researchers who apply through Public Health England’s Office for Data Release, with a specific health-care related research question and appropriate research ethics permissions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/09/2018 16:38:09 answering member 4067 label Biography information for Steve Brine
tabling member	1591 label Biography information for Tim Farron

969083

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of levels of funding on the ability of the NHS to increase access to radiotherapy.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	171339
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>Since 2016, the Radiotherapy Modernisation programme has seen £130 million of new funding invested in improving radiotherapy equipment. As a result, the National Health Service has so far received 73 new or upgraded linear accelerators, enabling the delivery of advanced treatment techniques and faster treatment times. From April 2019, NHS England will be establishing 11 Radiotherapy Networks to build on this investment and lead the development of services at a local level. This will include ensuring that every patient benefits from best clinical practice and has access to innovative and advanced treatments and techniques.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 15:02:53 answering member 4067 label Biography information for Steve Brine
tabling member	3973 label Biography information for Grahame Morris

969086

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how NHS England monitors clinical commissionng groups' cancer treatment performance in respect of access to advanced radiotherapy; and what steps NHS England takes to address instances of poor performance.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	171340
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>Clinical commissioning groups are not responsible for ensuring access to advanced radiotherapy techniques, such as Intensity Modulated Radiotherapy (IMRT). The commissioning of all radiotherapy in England is the responsibility of NHS England’s Specialised Commissioning team. Access to IMRT is monitored against a national average access standard of 25%, performance against this standard is consistently around 45%. From April 2019, Radiotherapy Networks, working in close partnership with Specialised Commissioners and Cancer Alliances, will play a key role in increasing access to both advanced and innovative radiotherapy, as well as ensuring adherence to best practice treatment protocols.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 170800 question first answered 11/09/2018 14:23:08 answering member 4067 label Biography information for Steve Brine
tabling member	3973 label Biography information for Grahame Morris

968146

registered interest
date	05/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the performance of Clinical Commissioning Groups to improve access to advanced radiotherapy.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	170800
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>Clinical commissioning groups are not responsible for ensuring access to advanced radiotherapy techniques, such as Intensity Modulated Radiotherapy (IMRT). The commissioning of all radiotherapy in England is the responsibility of NHS England’s Specialised Commissioning team. Access to IMRT is monitored against a national average access standard of 25%, performance against this standard is consistently around 45%. From April 2019, Radiotherapy Networks, working in close partnership with Specialised Commissioners and Cancer Alliances, will play a key role in increasing access to both advanced and innovative radiotherapy, as well as ensuring adherence to best practice treatment protocols.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171340 question first answered 11/09/2018 14:23:08 answering member 4067 label Biography information for Steve Brine
tabling member	3973 label Biography information for Grahame Morris

919198

registered interest
date	07/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of the £130 million allocated to modernise radiotherapy has been spent on new linac machines for newly commissioned satellite centres.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	151134
answer	answer is ministerial correction date of answer 14/06/2018 answer text <p>The purpose of the £130 million modernisation fund was to upgrade or replace existing, older radiotherapy equipment. None of this funding was therefore spent on new equipment for newly commissioned satellite centres. Future funding decisions, including on new satellite centres, will be made after the fund ends in October 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/06/2018 10:56:11 answering member 4067 label Biography information for Steve Brine
tabling member	1591 label Biography information for Tim Farron

915098

registered interest
date	01/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to allocate funding to more efficient forms of radiotherapy technology; and if he will make a statement.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	148714
answer	answer is ministerial correction date of answer 06/06/2018 answer text <p>Significant investments have been, and continue to be, made to improve both the efficiency of radiotherapy equipment and the range of more innovative radiotherapy treatments that are routinely available to patients:</p><p>- In October 2016, NHS England announced a £130 million fund to modernise radiotherapy across England, ensuring that older linear accelerators (LINACs - radiotherapy machines) are either upgraded or replaced. These upgraded/new machines will deliver both a wider range of innovative treatment techniques and are also significantly faster, enabling more patients to benefit from the latest technology regardless of where they live;</p><p>- NHS England has also committed £15 million over three years to evaluate the benefits of stereotactic ablative radiotherapy (SABR) in the treatment of a number of new clinical indications. SABR is an innovative radiotherapy technique that more precisely targets cancers with radiotherapy, reducing the damage to the surrounding tissues. A further £6 million was also committed by NHS England to support a number of Cancer Research UK sponsored SABR clinical trials. It is envisaged that the results of both the trials and the evaluation programme will enable more patients to routinely access SABR treatments;</p><p>- Following an investment of £23 million to improve access to Intensity Modulated Radiotherapy (IMRT), another more precise form of radiotherapy with fewer side effects, the National Health Service is now regularly exceeding access standards, meaning that more people are benefiting from this treatment. The percentage of radiotherapy patients who received IMRT increased from 10% (1,660) in April to June 2012 to 44% (8,865) in January to March 2017. The current access standard is 24%; and</p><p>- In 2012, the Government provided £250 million to build two proton beam therapy centres in England (at University College London Hospital and The Christie in Manchester), the first of which will become operational in autumn 2018.</p><p>No assessment has been made of the effect of national prices for radiotherapy treatment.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 148715 question first answered 06/06/2018 16:01:48 answering member 4067 label Biography information for Steve Brine
tabling member	1591 label Biography information for Tim Farron

915099

registered interest
date	01/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the internal market tariff on the effectiveness of the NHS delivery of radiotherapy.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	148715
answer	answer is ministerial correction date of answer 06/06/2018 answer text <p>Significant investments have been, and continue to be, made to improve both the efficiency of radiotherapy equipment and the range of more innovative radiotherapy treatments that are routinely available to patients:</p><p>- In October 2016, NHS England announced a £130 million fund to modernise radiotherapy across England, ensuring that older linear accelerators (LINACs - radiotherapy machines) are either upgraded or replaced. These upgraded/new machines will deliver both a wider range of innovative treatment techniques and are also significantly faster, enabling more patients to benefit from the latest technology regardless of where they live;</p><p>- NHS England has also committed £15 million over three years to evaluate the benefits of stereotactic ablative radiotherapy (SABR) in the treatment of a number of new clinical indications. SABR is an innovative radiotherapy technique that more precisely targets cancers with radiotherapy, reducing the damage to the surrounding tissues. A further £6 million was also committed by NHS England to support a number of Cancer Research UK sponsored SABR clinical trials. It is envisaged that the results of both the trials and the evaluation programme will enable more patients to routinely access SABR treatments;</p><p>- Following an investment of £23 million to improve access to Intensity Modulated Radiotherapy (IMRT), another more precise form of radiotherapy with fewer side effects, the National Health Service is now regularly exceeding access standards, meaning that more people are benefiting from this treatment. The percentage of radiotherapy patients who received IMRT increased from 10% (1,660) in April to June 2012 to 44% (8,865) in January to March 2017. The current access standard is 24%; and</p><p>- In 2012, the Government provided £250 million to build two proton beam therapy centres in England (at University College London Hospital and The Christie in Manchester), the first of which will become operational in autumn 2018.</p><p>No assessment has been made of the effect of national prices for radiotherapy treatment.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 148714 question first answered 06/06/2018 16:01:48 answering member 4067 label Biography information for Steve Brine
tabling member	1591 label Biography information for Tim Farron